← Leaderboards
Jenny E Gumperz
Brigham And Women'S Hospital
$7,778,810
Attributed
$7,992,622
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $706.8K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,992,622 · 9
By mechanism
R01$6,028,877 · 4
R21$1,633,500 · 4
R56$330,245 · 1
Top collaborators
- Igor I Slukvin2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Michael B Brenner$54,001,662
- David Branch Moody$37,151,091
- Robert C Fuhlbrigge$3,933,073
- Karsten Gronert$6,688,446
- Manfred Brigl$4,816,527
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsAntigensMediatingLipidsBaseIn VivoT-LymphocytePropertyMolecularImmuneCell PhysiologyPathway InteractionsCytokineGlycolipidsInflammatoryResponseGrantMonocyteSignal TransductionClone CellsCd1d AntigenImmune ResponseProductionAntigen Presentation
Grant awards (29)
Development of iPSC-derived iNKT cells to promote hematopoietic engraftment$194,375
R21 · FY2023 · AI · contact PI
Mechanisms of iNKT cell anti-viral adjuvancy$382,500
R01 · FY2022 · AI · contact PI
Development of iPSC-derived iNKT cells to promote hematopoietic engraftment$233,250
R21 · FY2022 · AI · contact PI
Mechanisms of iNKT cell anti-viral adjuvancy$382,500
R01 · FY2021 · AI · contact PI
Mechanisms of iNKT cell anti-viral adjuvancy$382,500
R01 · FY2020 · AI · contact PI
Mechanisms of iNKT cell anti-viral adjuvancy$382,500
R01 · FY2019 · AI · contact PI
Mechanisms of iNKT cell anti-viral adjuvancy$382,500
R01 · FY2018 · AI · contact PI
Understanding the impact of human NKT cells on hematopoiesis$191,250
R21 · FY2016 · AI · contact PI
Understanding the impact of human NKT cells on hematopoiesis$229,500
R21 · FY2015 · AI · contact PI
Analysis of Human NKT cell auto-antigens$337,592
R01 · FY2013 · AI · contact PI
Analysis of human NKT cells in GVHD in vivo$188,125
R21 · FY2013 · AI · contact PI
Analysis of Human NKT cell auto-antigens$359,141
R01 · FY2012 · AI · contact PI
Analysis of human NKT cells in GVHD in vivo$225,750
R21 · FY2012 · AI · contact PI
Analysis of Human NKT cell auto-antigens$359,141
R01 · FY2011 · AI · contact PI
Analysis of Human NKT cell auto-antigens$362,769
R01 · FY2010 · AI · contact PI
Functional analysis of human NKT cells and myeloid DCs within murine SCID hosts$185,625
R21 · FY2010 · AI · contact PI
Analysis of Human NKT cell auto-antigens$158,389
R01 · FY2010 · AI · contact PI
Analysis of Human NKT cell auto-antigens$237,797
R01 · FY2009 · AI · contact PI
Functional analysis of human NKT cells and myeloid DCs within murine SCID hosts$185,625
R21 · FY2009 · AI · contact PI
Functions of NKT cell autoreactivity$330,245
R56 · FY2008 · AI · contact PI
Structural determinants of CD1d-restricted TCR function$268,058
R01 · FY2008 · AI · contact PI
Structural determinants of CD1d-restricted TCR function$273,328
R01 · FY2007 · AI · contact PI
Structural determinants of CD1d-restricted TCR function$281,569
R01 · FY2006 · AI · contact PI
CD1d-restricted T cells and anti-phospholipid antibodies$210,677
R01 · FY2006 · HL · contact PI
Structural determinants of CD1d-restricted TCR function$288,422
R01 · FY2005 · AI
CD1d-restricted T cells and anti-phospholipid antibodies$215,748
R01 · FY2005 · HL
Structural determinants of CD1d-restricted TCR function$288,498
R01 · FY2004 · AI
CD1d-restricted T cells and anti-phospholipid antibodies$215,748
R01 · FY2004 · HL
CD1d-restricted T cells and anti-phospholipid antibodies$259,500
R01 · FY2003 · HL